Anthera Pharmaceuticals Inc (ANTH PINK) stock market data APIs
$0.0001
0(0%)
as of September 16, 2025
Try our APIs with
free plan!
Anthera Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Prev. Close
0.0001
Open
0.0001
High
0.0001
Low
0.0001
52 wk Range
0.0001-0.0002
Market Cap
618 K
Shares Outstanding
26 179 K
EPS
0
Beta
-96.751
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Anthera Pharmaceuticals Inc data using free add-ons & libraries
Get Anthera Pharmaceuticals Inc Fundamental Data
Anthera Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -36 402 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-18
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Anthera Pharmaceuticals Inc News
New
Amazon's AWS CEO: We're building the building blocks of AI
Amazon's (AMZN) AWS is still a dominant player in the cloud wars, but its slower growth has some investors sitting on the sidelines. "We're in the very early stages, but there is such enormous promis...
Goldman Sachs analyst bets AI will give software companies a 'rebirth'
AI isn't killing software — it's giving it a "rebirth." "AI is going to work with software, and it's going to be a force multiplier for software," Goldman Sachs analyst Kash Rangan told Yahoo Finan...
JPMorgan initiates Anthem Biosciences stock with Neutral rating
Investing.com - JPMorgan has initiated coverage on Anthem Biosciences (ANTHEM:IN) with a Neutral rating and a price target of INR820.00. The investment bank describes Anthem as an innovation-led, tec...
The legal pushback that could complicate Trump's AI plan
The Trump administration’s new “Action Plan” to support US dominance in artificial intelligence is all but certain to be met with legal pushback, especially from civil rights advocates and copyr...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
